Sarepta won't resume enrollment in Elevidys confirmatory Phase 3 trial

Sarepta Therapeutics will not resume enrollment in the confirmatory Phase 3 trial of Elevidys, which has been on hold since a second patient death last year.

Detected & updated continuously · Source: Nebula